Study on BMS-986340 Alone and with Nivolumab or Docetaxel for Advanced Solid Tumors

Inclusion Criteria

• Must provide a fresh tumor sample before and during treatment for analysis.
• Must have a measurable tumor that can be biopsied, according to specific medical criteria.
• Must be in good overall health, with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Must have cancer that has progressed after the most recent treatment.
• Must have received standard treatments, except for those who have previously used Docetaxel for advanced cancer.
• Must have advanced or metastatic cancer and have tried all other available treatments or be unable to tolerate them.

Exclusion Criteria

• Women who are pregnant or breastfeeding.
• Have a primary cancer in the central nervous system (CNS).
• Have untreated cancer that has spread to the CNS.
• Have cancer that has spread to the membranes surrounding the brain and spinal cord.
• Have another active cancer or a history of cancer that was active within the last two years.
• Have an active or suspected autoimmune disease.
• Require treatment with steroids or other immune-suppressing drugs within a certain timeframe before starting the study.
• Have had an organ or tissue transplant.
• Have uncontrolled or serious heart disease.
• Have had major surgery within four weeks before starting the study.
• Have a history of lung diseases like interstitial lung disease or pulmonary fibrosis.